DLBCL: Clinical Trials

7 trials for DLBCL, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 7
Phase 22Completed 2

Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Cyclophosphamide, Fludarabine, ACE1831 - B-cell Lymphoma, Non Hodgkin Lymphoma
Phase 1CompletedAcepodia Biotech, Inc.162023-01-212026-06-30
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
KT-413 - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Phase 1CompletedKymera Therapeutics, Inc.72022-06-132024-12-10
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine - Malignancy, Non-hodgkin Lymphoma
Phase 1 / Phase 2CompletedCyteir Therapeutics, Inc.1692019-10-092024-12-24
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Fludarabine, Cyclophosphamide, CD22 CAR - B-ALL, B-cell Non Hodgkin Lymphoma
Phase 1CompletedMatthew Frank522019-09-122026-03-30
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
AZD9150, Acalabrutinib, AZD6738 - NHL, DLBCL
Phase 1CompletedAcerta Pharma BV302018-06-192022-08-15
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
IONIS-STAT3Rx - Advanced Cancers, DLBCL
Phase 1 / Phase 2CompletedIonis Pharmaceuticals, Inc.642012-02-272018-06-25
A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects
TL011, Rituximab - DLBCL
Phase 1CompletedTeva Branded Pharmaceutical Products R&D, Inc.1862010-09-012013-10-22

Narrower conditions

Lymphoma, Non-Hodgkin (4)  ·  Lymphoma, B-Cell (2)  ·  Lymphoma, Follicular (2)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Breast Neoplasms (1)  ·  Burkitt Lymphoma (1)  ·  Head and Neck Neoplasms (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Multiple Myeloma (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Sarcoma (1)

Broader conditions

Hemic and Lymphatic Diseases (6)  ·  Immune System Diseases (6)  ·  Immunoproliferative Disorders (6)  ·  Lymphatic Diseases (6)  ·  Lymphoproliferative Disorders (6)  ·  Neoplasms by Histologic Type (6)  ·  Lymphoma (5)  ·  Neoplasms (5)  ·  Lymphoma, B-Cell (2)  ·  Adnexal Diseases (1)  ·  Blood Protein Disorders (1)  ·  Breast Diseases (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Bronchogenic (1)

Interventions

Rituximab (3)  ·  Cyclophosphamide (2)  ·  fludarabine (2)  ·  AZD5153 (1)  ·  Bendamustine Hydrochloride (1)  ·  Capecitabine (1)  ·  Gemcitabine (1)  ·  MZ1 compound (1)  ·  acalabrutinib (1)  ·  ceralasertib (1)  ·  danvatirsen (1)  ·  magrolimab (1)  ·  obinutuzumab (1)

Sponsors

Acepodia Biotech, Inc. (1)  ·  Acerta Pharma BV (1)  ·  Cyteir Therapeutics, Inc. (1)  ·  Ionis Pharmaceuticals, Inc. (1)  ·  Kymera Therapeutics, Inc. (1)  ·  Matthew Frank (1)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (1)

Countries

United States (6)  ·  United Kingdom (2)  ·  Bulgaria (1)  ·  Estonia (1)  ·  France (1)  ·  Hong Kong (1)  ·  Hungary (1)  ·  Italy (1)  ·  Latvia (1)  ·  Poland (1)  ·  Russia (1)  ·  Spain (1)  ·  Taiwan (1)  ·  Ukraine (1)

Top investigators

Ashwin Gollerkeri, MD (1)  ·  Ian Flinn, MD, PhD (1)  ·  Mariano Provencio, MD, PhD (1)  ·  Markus Renschler, MD (1)  ·  Matthew Frank, MD, PhD (1)  ·  Steve Hughes, MD (1)

Results publications

PMID 30446007, PMID 33512414, PMID 38996463

NIH funding

2017 (1), K08CA248968 (1)